Clinical trial · Interventional
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
GRAVITAS-119: A Single-Arm, Open-Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
NCT03320642CI-TRIAL-00096702terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study terminated by sponsor
Summary
Brief summary (as posted)
The purpose of this study is to assess the impact and safety of itacitinib in combination with calcineurin inhibitor (CNI)-based interventions for the prophylaxis of graft-versus-host-disease (GVHD).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Calcineurin inhibitor | Drug | — | UNRESOLVED |
| Itacitinib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Itacitinib + Calcineurin Inhibitor (CNI) -Based Interventions
- description
- Itacitinib in combination with a CNI-based intervention.
- interventionNames
- Drug: Itacitinib
- Drug: Calcineurin inhibitor
Primary outcomes (1)
- measure
- Proportion of participants with hematologic recovery when itacitinib is added to GVHD prophylaxis treatment
- timeFrame
- Day 28
- description
- Hematologic recovery defined as demonstrating both neutrophil recovery (ANC ≥ 500/mm\^3 for 3 consecutive measurements) and platelet recovery (platelet count ≥ 20,000/mm\^3 with no requirement for platelet transfusion in the preceding 3 days).
Secondary outcomes (11)
- measure
- GVHD relapse-free survival rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects with acute leukemia, chronic myelogenous leukemia, or myelodysplasia with no circulating blasts and \< 5% blasts in the bone marrow. * Subjects with non-Hodgkin lymphoma, including but not limited to chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular, marginal zone, diffuse large B cell, or mantle cell lymphoma must have chemosensitive disease at time of transplant. Subjects with Hodgkin lymphoma with chemosensitive disease at the time of transplant. * Must be candidates for reduced-intensity conditioning regimens. * Must be candidates for peripheral blood stem cell transplants. * Karnofsky Performance Status score ≥ 70% or Eastern Cooperative Oncology Group Performance Status score of 0 to 2. * Serum creatinine ≤ 2.0 mg/dL or creatinine clearance ≥ 40 mL/min measured or calculated by Cockcroft-Gault equation. * Be willing to avoid pregnancy or fathering children. Exclusion Criteria: * Has previously received an allogenic hematopoietic stem cell transplant. * Presence of an active uncontrolled infection. * Known HIV infection. * Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection that requires treatment or at risk for HBV reactivation. * Prior malignancies. * Severe organ dysfunction. * Prior treatment with a JAK inhibitor or with an investigational agent, device, or procedure within 21 days of enrollment. * Currently breastfeeding. * Known allergies, hypersensitivity, or intolerance to any of the study medications. * Receipt of live (including attenuated) vaccines during the study, or anticipation of need for such a vaccine during the study. * History of primary idiopathic myelofibrosis or any severe marrow fibrosis that would prolong neutrophil engraftment to \> 28 days after transplant. * Post-transplant maintenance therapy for the hematologic malignancy or plans to initiate maintenance therapy during study treatment.
References
Publications (0)
Data not yet available
No reference posted for this study.